Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients.
African-Americans (AA) have higher acute rejection rates and poorer long-term graft survival rates when compared with non-AA. It is yet to be demonstrated that the type of induction therapy modifies outcomes in this 'high-risk' population. This retrospective analysis compares the efficacy of induction therapy [antilymphocyte antibodies (ALA) versus interleukin-2 receptor antagonists (IL-2RA)] in the AA population. Some 189 AAs were included. There was no difference in acute rejection at one year between the groups (ALA (12%) or IL-2RA (12%), P = 0.89). Type of induction therapy had no significant effect on death-censored (P = 0.61) or uncensored graft survival (P = 0.32). There was no difference between CMV or BK virus infections between the groups (P = 0.14 and 0.94 respectively). Type of induction therapy does not appear to affect acute rejection rates or long-term graft survival in low-risk AA kidney transplant recipients.
Fleming
James N
JN
Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC 29425, USA.
Taber
David J
DJ
Weimert
Nicole A
NA
Egidi
Maria F
MF
McGillicuddy
John
J
Bratton
Charles F
CF
Lin
Angello
A
Chavin
Kenneth D
KD
Baliga
Prabhakar K
PK
D000328:Adult; D001741:Black or African American; D000961:Antilymphocyte Serum / Q000276:immunology*; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D016030:Kidney Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012306:Risk; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit